Marked transfection enhancement by the DPL
(DNA/peptide/lipid) complex
- Author(s)
- IK-JAE MOON; HYUNGU KANG; YOUNG-BAE SEU; BYEONG-CHURL CHANG; DAE-KYU SONG; JONG-GU PARK
- Keimyung Author(s)
- Jang, Byeong Churl; Park, Jong Gu; Song, Dae Kyu
- Department
- Dept. of Molecular Medicine (분자의학)
Dept. of Physiology (생리학)
- Journal Title
- International Journal of Molecular Medicine
- Issued Date
- 2007
- Volume
- 20
- Issue
- 4
- Abstract
- . A short peptide, corresponding to the nuclear
localization signal of the human immunodeficiency virus-1
Tat protein, Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg, was
modified by adding a cysteine residue at the COOH terminus.
The peptide was mixed with a reporter plasmid, and then
with cationic lipids, to form a tripartite complex, DNA/
peptide/lipid (DPL). Various cell lines were treated with the
DPL complex and compared for transfection efficiency with
those of the conventional DNA/lipid (DL) complex. With the
simple inclusion of the peptide, the DPL complex showed
much enhanced transfection. Meanwhile, the plasmid DNA
mixed only with the peptide exhibited some improvement but
with much lower transfection than the DPL complex. When
the DPL complex was formed with various cationic lipids,
the DOSPA/DOPE exhibited superior transfection efficiency
than the other cationic lipids tested at the optimal ratio of
1:3:5 (w:w:w) in many cell types. At the optimal ratio of the
DPL components, transfection efficiency was routinely
shown to be ~10-fold higher for reporter gene expression
than that of the conventional DL complex. Furthermore,
when subcutaneous tumors of a colon cancer cell line
(SW480) were treated intratumorally with antisense oligos,
k-ras-RiAS, delivered as a DPL complex, tumor growth was
markedly suppressed. This study shows that the DPL
complex, which is easy to formulate by ordered mixing, can
be employed for a much enhanced cellular uptake of a
transgene both in vitro and in vivo.
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.